Motivational Strategies in Batterer Intervention Programs for Offenders With Alcohol/Drug Abuse Problems (IMP-ADAPs) (IMP-ADAPs)

December 5, 2023 updated by: University of Valencia

Motivational Strategies in Batterer Intervention Programs for Intimate Partner Violence Offenders With Alcohol/Drug Abuse Problems: An Experimental Study

Alcohol and/or drug abuse problems (ADAPs) have been consistently identified in the scientific literature as a risk factor of intimate partner violence against women (IPVAW). Around 50% of IPVAW offenders referred to batterer intervention programs (BIPs) have ADAPs. ADAPs are also one of the main predictors of BIPs dropout. In Spain, the majority of BIPs do not fit the intervention to specific needs or characteristics of IPVAW offenders, such as those with ADAPs. The aim of this research is to assess the effectiveness of a new motivational strategy adapted to IPVAW offenders with ADAPs, aiming to increase treatment adherence and to improve BIPs outcomes. The motivational strategy will include an individualized motivational plan (IMP) developed for each participant with ADAPs (IMP-ADAPs). In these IMPs one of the main aims will be to reduce alcohol and/or drug consumption. The current study will use a randomized control trial. Participants with ADAPs will be allocated to one of two treatment conditions: experimental condition: Standard batterer intervention program (SBIP) plus individualized motivational plan focused in ADAPs (SBIP+ ADAPs-IMP), and control condition: Standard batterer intervention program plus individualized motivational plan (SBIP+IMP). Primary/final outcomes will be recidivism and ADAPs reduction. Secondary/proximal outcomes will include treatment adherence related variables, violence related attitudes and attributions, self-control and psychological adjustment. Outcome variables will be assessed at baseline, at the end of the intervention, and at six months after the intervention will be finished.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
80

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Spain
      • Valencia, Spain, 46010
        • Recruiting
        • Faculty of Psychology
        • Contact:
          • Elena Terreros, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Males convicted of IPV against their partner or ex-partner
  • Alcohol and/or drugs abuse problems

Exclusion Criteria:

  • No current severe psychological disorders

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: SBIP+ ADAPs-IMP
Experimental condition: Standard batterer intervention program (SBIP) plus individualized motivational plan (IMP) focused in alcohol and/or drugs abuse problems (ADAPs).
Behavioral: SBIP+ ADAPs-IMP
Standard batterer intervention program plus Individualized Motivational Plans adapted to alcohol and/or drug abuse problems. The SBIP consist of 70 hr of a cognitive-behavioral intervention including discussion topics such as sexism, sex roles, and gender equality. The intervention phase consisted of six modules in which different intervention techniques were applied (i.e., group dynamics, roleplaying, videos, training in cognitive restructuring, emotion management skills). The IMP included a set of motivational strategies to increase treatment compliance and motivation for change and had four main strategies: (a) five individual motivational interviews, to identify IPV related personal goals and follow up their achievement (in this case, one of the goals has to be related to ADAPs); (b) three group sessions where participants share their goals; (c) therapists follow-up and reinforcement of participants' goals; and (d) use of retention techniques.
Active Comparator: SBIP+IMP
Control condition: Standard batterer intervention program plus individualized motivational plan (SBIP+IMP)
Behavioral: SBIP+IMP
Standard batterer intervention program plus Individualized Motivational Plans. The SBIP consist of 70 hr of a cognitive-behavioral intervention including discussion topics such as sexism, sex roles, and gender equality. The intervention phase consist of six modules in which different intervention techniques are applied (i.e., group dynamics, roleplaying, videos, training in cognitive restructuring, emotion management skills). The IMP include a set of motivational strategies to increase treatment compliance and motivation for change and has four main strategies: (a) five individual motivational interviews, to identify IPV related personal goals and follow up their achievement; (b) three group sessions where participants share their goals, explain their progress to the group, and receive feedback, support and advice from the group; (c) therapists follow-up and reinforcement of participants' goals; and (d) use of retention techniques.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in alcohol abuse problems
Time Frame: At baseline, at 12 months (end of intervention), and at 18 months (follow-up)
Alcohol Use Disorders Identification Test. Saunders, Aasland, Babor, De la Fuente, & Grant, 1993. Total scale range: 0-20 (Higher values indicate worse outcome).
At baseline, at 12 months (end of intervention), and at 18 months (follow-up)
Change in cannabis abuse problems
Time Frame: At baseline, at 12 months (end of intervention), and at 18 months (follow-up)
Severity Dependence Scale. Gossop et al., 1995. Total scale range: 0-15 (Higher values indicate worse outcome).
At baseline, at 12 months (end of intervention), and at 18 months (follow-up)
Change in cocaine abuse problems
Time Frame: At baseline, at 12 months (end of intervention), and at 18 months (follow-up)
Severity Dependence Scale. Gossop et al., 1995. Total scale range: 0-15 (Higher values indicate worse outcome).
At baseline, at 12 months (end of intervention), and at 18 months (follow-up)
Change in self-reported physical intimate partner violence against women
Time Frame: At baseline, at 12 months (end of intervention), and at 18 months (follow-up)
Self-reported physical violence sub-scale from the Conflict Tacticts Scale. Straus, Hamby, Boney-McCoy y Sugarman, 1996. Total scale range: 0-72 (Higher values indicate worse outcome).
At baseline, at 12 months (end of intervention), and at 18 months (follow-up)
Change in self-reported psychological intimate partner violence against women
Time Frame: At baseline, at 12 months (end of intervention), and at 18 months (follow-up)
Self-reported psychological violence sub-scale from the Conflict Tacticts Scale. Straus, Hamby, Boney-McCoy y Sugarman, 1996. Total scale range: 0-72 (Higher values indicate worse outcome).
At baseline, at 12 months (end of intervention), and at 18 months (follow-up)
Change in risk of recidivism
Time Frame: At baseline, at 12 months (end of intervention), and at 18 months (follow-up)
The Spousal Assault Risk Assessment. SARA; Kropp y Hart, 2000. Total scale range: 0-40 (Higher values indicate worse outcome)
At baseline, at 12 months (end of intervention), and at 18 months (follow-up)
Police-reported recidivism
Time Frame: At 18 months (follow-up)
Ministry of Home Affairs' monitoring system for IPV. This system includes information on further incidents of violence by individuals convicted of IPV and reported by any of the institutions involved in victim protection services. Recidivism will be considered to have occurred when this information appear in the system in the 6 months after completing the intervention.
At 18 months (follow-up)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Therapeutic alliance
Time Frame: 4 weeks after the first session of the intervention
Working Alliance Inventory Shortened Observer-rated version (WAI-O-S; Tichenor & Hill, 1989). Total scale range: 0-74 (Higher values indicate better outcome)
4 weeks after the first session of the intervention
Change in motivation
Time Frame: At baseline, at 6 months, and at 12 months (end of intervention)
Based on the transtheoretical model of change (Prochaska and DiClemente, 1982; Prochaska et al., 1992), therapists will rate participants' stage of change (pre-contemplation, contemplation, preparation, action, and maintenance). Total range: 1-5 (Higher values indicate better outcome).
At baseline, at 6 months, and at 12 months (end of intervention)
Change in impulsivity
Time Frame: At baseline and at 12 months (end of intervention)
Plutchik Impulsivity Scale; Plutchnik y Van Pragg, 1989. Total scale range: 11-44 (Higher values indicate worse outcome)
At baseline and at 12 months (end of intervention)
Change in depressive symptomatology
Time Frame: At baseline and at 12 months (end of intervention)
Spanish reduced version of the Center for Epidemiology Studies-Depression Scale; Herrero y Gracia, 2007. Total scale range: 7-28 (Higher values indicate worse outcome)
At baseline and at 12 months (end of intervention)
Change in self-esteem
Time Frame: At baseline and at 12 months (end of intervention)
Rosenberg Self-Esteem Scale. Rosenberg, 1965. Total scale range: 10-40 (Higher values indicate better outcome)
At baseline and at 12 months (end of intervention)
Attributions of Responsibility
Time Frame: At baseline and at 12 months (end of intervention)
Intimate Partner Violence Responsibility Atribution Scale. Lila, Oliver, Catalá-Miñana, Galiana y Gracia, 2014. Three sub-scales: responsibility attribution to the legal system (sub-scale range: 4-20), responsibility attribution to the victim (sub-scale range: 4-20), and responsibility attribution to the offender personal context (sub-scale range: 4-20). Higher values indicate worse outcome.
At baseline and at 12 months (end of intervention)
Change in perceived severity of intimate partner violence against women
Time Frame: At baseline and at 12 months (end of intervention)
Severity Perception of Intimate Partner Violence Against Women Scale. Gracia, García y Lila (2011). Total scale range: 8-80 (Higher values indicate better outcome)
At baseline and at 12 months (end of intervention)
Change in acceptability of intimate partner violence against women
Time Frame: At baseline and at 12 months (end of intervention)
Acceptability of Intimate Partner Violence Against Women Scale. Martín-Fernández, Gracia, Marco, Vargas, Santirso and Lila (2018). Total scale range: 0-40 (Higher values indicate worse outcome)
At baseline and at 12 months (end of intervention)
Change in benevolent sexism
Time Frame: At baseline and at 12 months (end of intervention)
Ambivalent Sexism Inventory. Glick y Fiske, 1996. Two sub-scales: Benevolent sexism (sub-scale range: 0-55) and Hostile sexism (sub-scale range: 0-55). Higher values indicate worse outcome
At baseline and at 12 months (end of intervention)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Valencia

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Ministerio de Sanidad, Servicios Sociales e Igualdad

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Marisol Lila, PhD, University of Valencia

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 4, 2019

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 30, 2025

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 30, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 5, 2019

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 19, 2019

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 21, 2019

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
December 6, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 5, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
December 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • H1537520365110

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings